Unknown

Dataset Information

0

An in vitro assay for enzymatic studies on human ALG13/14 heterodimeric UDP-N-acetylglucosamine transferase.


ABSTRACT: The second step of eukaryotic lipid-linked oligosaccharide (LLO) biosynthesis is catalyzed by the conserved ALG13/ALG14 heterodimeric UDP-N-acetylglucosamine transferase (GnTase). In humans, mutations in ALG13 or ALG14 lead to severe neurological disorders with a multisystem phenotype, known as ALG13/14-CDG (congenital disorders of glycosylation). How these mutations relate to disease is unknown because to date, a reliable GnTase assay for studying the ALG13/14 complex is lacking. Here we describe the development of a liquid chromatography/mass spectrometry-based quantitative GnTase assay using chemically synthesized GlcNAc-pyrophosphate-dolichol as the acceptor and purified human ALG13/14 dimeric enzyme. This assay enabled us to demonstrate that in contrast to the literature, only the shorter human ALG13 isoform 2, but not the longer isoform 1 forms a functional complex with ALG14 that participates in LLO synthesis. The longer ALG13 isoform 1 does not form a complex with ALG14 and therefore lacks GnTase activity. Importantly, we further established a quantitative assay for GnTase activities of ALG13- and ALG14-CDG variant alleles, demonstrating that GnTase deficiency is the cause of ALG13/14-CDG phenotypes.

SUBMITTER: Wang CD 

PROVIDER: S-EPMC9527342 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature

altmetric image

Publications

An <i>in vitro</i> assay for enzymatic studies on human ALG13/14 heterodimeric UDP-<i>N</i>-acetylglucosamine transferase.

Wang Chun-Di CD   Xu Si S   Chen Shuai S   Chen Zheng-Hui ZH   Dean Neta N   Wang Ning N   Gao Xiao-Dong XD  

Frontiers in cell and developmental biology 20220919


The second step of eukaryotic lipid-linked oligosaccharide (LLO) biosynthesis is catalyzed by the conserved ALG13/ALG14 heterodimeric UDP-<i>N</i>-acetylglucosamine transferase (GnTase). In humans, mutations in ALG13 or ALG14 lead to severe neurological disorders with a multisystem phenotype, known as ALG13/14-CDG (congenital disorders of glycosylation). How these mutations relate to disease is unknown because to date, a reliable GnTase assay for studying the ALG13/14 complex is lacking. Here we  ...[more]

Similar Datasets

| S-EPMC2583287 | biostudies-literature
| S-EPMC2486831 | biostudies-literature
| S-EPMC3325803 | biostudies-literature
| S-EPMC7692735 | biostudies-literature
| S-EPMC8758813 | biostudies-literature
| S-EPMC142877 | biostudies-literature
2018-09-24 | PXD006635 | Pride
| S-EPMC2414269 | biostudies-literature
| S-EPMC2673340 | biostudies-literature
| S-EPMC4062475 | biostudies-literature